多拉韦林在人离体胎盘小叶灌注模型中的胎盘转运
研究采用开放式离体双重灌注人胎盘小叶模型,在母体灌注液理论多拉韦林浓度250 ng/mL条件下评估其母胎转运。五项实验显示胎儿与母体浓度比为16%,清除指数为48%,提示多拉韦林既可穿过胎盘又可在胎盘组织蓄积,其孕期安全性与疗效尚需进一步研究。
要点
- 多拉韦林可穿过人胎盘并在胎盘组织中蓄积
- 胎儿与母体浓度比中位数为16%,清除指数中位数为48%
- 潜在用于母婴阻断,但需警惕胎儿毒性并进一步验证
核心结论
- 多拉韦林既能穿过胎盘又能在胎盘组织中蓄积,可能有助于暴露前后预防以降低垂直传播风险,但存在胎儿毒性潜在风险,孕期安全性和有效性需进一步研究。
研究设计与样本
- 采用开放式离体双重灌注人胎盘小叶模型研究母胎转运,母体灌注液理论多拉韦林浓度为250 ng/mL,含2 g/L人白蛋白和20 g/L安替比林作为活力标记,双重灌注最长90分钟,共五项实验。
主要发现
- 母体与胎儿腔室多拉韦林浓度中位数(IQR)分别为303(178-420)和40(30-54)ng/mL。
- 胎儿与母体浓度比为16%(12%-18%),清除指数(与安替比林转运比较)为48%(35%-64%)。
- 胎盘组织蓄积指数中位数为39%(范围10%-66%)。
临床怎么用
- 提示多拉韦林可能作为母婴阻断的暴露前后预防用药,但现有离体数据不足以支持孕期临床用药决策。
局限性
- 仅为离体胎盘小叶灌注模型,样本为五项实验,缺乏孕期体内安全性与暴露数据,胎儿毒性风险尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent HIV-1 NNRTI doravirine is likely to be used in pregnant women despite the complete lack of data on safety and exposure in the fetus. The objective of this study was to determine its placental transfer. METHODS: Maternal-to-fetal transfer was investigated using the open-circuit ex vivo dually perfused human cotyledon model. Doravirine was added to a maternal perfusate (theoretical doravirine concentration of 250 ng/mL) containing 2 g/L human albumin and 20 g/L antipyrine, a marker to validate the cotyledon's viability, and cotyledons were dually perfused for up to 90 min. RESULTS: In five experiments, the median (IQR) doravirine concentrations in the maternal and fetal compartments were, respectively, 303 (178-420) and 40 (30-54) ng/mL, the fetal-to-maternal ratio was 16% (12%-18%) and the clearance index (in comparison with antipyrine transfer) was 48% (35%-64%). The median accumulation index in cotyledon tissue was 39% (range 10%-66%). CONCLUSIONS: Doravirine both crosses and accumulates in the placenta. This may be useful as pre/post-exposure prophylaxis to reduce the risk of vertical HIV transmission but carries the potential for fetal toxicities. Further investigation is required to determine the safety and efficacy of this new antiretroviral agent in pregnancy.
引用
- Lê MP, Pencolé L, Peytavin G, et al. Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model. J Antimicrob Chemother. 2021. PMID: 34151361. doi:10.1093/jac/dkab202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。